Global Big Pharma Partnering Terms and Agreements Deals Directory 2012-2018

Dublin, April 17, 2018 -- The "Global Big Pharma Partnering Terms and Agreements 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Global Big Pharma Partnering Terms and Agreements 2012 to 2018 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes. This report provides details of the latest Big Pharma agreements announced in the life sciences since 2012.

The report takes the reader through a comprehensive review Big Pharma deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Big Pharma partnering deals.

The report presents financial deal term values for Big Pharma deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

One of the key highlights of the report is that over 3,000 online deal records of actual Big Pharma deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

Key benefits

• In-depth understanding of Big Pharma deal trends since 2012
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of Big Pharma agreements with real life case studies
• Detailed access to actual Big Pharma contracts entered into by leading biopharma companies
• Identify most active Big Pharma dealmakers since 2012
• Insight into terms included in a Big Pharma partnering agreement, with real world examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target
• Technology type
  

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Big Pharma dealmaking

2.1. Introduction
2.2. Big Pharma partnering over the years
2.3. Most active Big Pharma dealmakers
2.4. Big Pharma partnering by deal type
2.5. Big Pharma partnering by therapy area
2.6. Big Pharma partnering by technology type
2.7. Deal terms for Big Pharma partnering

Chapter 3 - Leading Big Pharma deals

3.1. Introduction
3.2. Top Big Pharma deals by value

Chapter 4 - Most active Big Pharma dealmakers

4.1. Introduction
4.2. Most active Big Pharma dealmakers
4.3. Most active Big Pharma partnering company profiles Including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others

Chapter 5 - Big Pharma contracts dealmaking directory

5.1. Introduction
5.2. Big Pharma contracts dealmaking directory

Chapter 6 - Big Pharma dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

For more information about this report visit https://www.researchandmarkets.com/research/q83533/global_big_pharma?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Pharmaceuticals